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surrounding the central focus of the report 
of S ö rensen  et al. , 5 most particularly those 
posed by the proposed role for TLR signal-
ing, are presented in  Figure 1 . 
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 Short-term effects of vitamin D 
receptor activation on serum 
creatinine, creatinine generation, 
and glomerular filtration 
 Matthew R.  Weir 1 
 Vitamin D receptor activation may have pleiotropic effects in a variety 
of tissues. Experimental studies with vitamin D receptor activation 
demonstrate an ability to delay progression of renal disease. In 
humans, vitamin D receptor activation reduces albuminuria. Yet some 
clinical studies demonstrate that patients receiving vitamin D 
supplementation have an elevation in serum creatinine and a decline 
in estimated glomerular filtration rate. These observations may be 
explainable by an effect of vitamin D receptor activation on creatinine 
metabolism. 
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 Vitamin D receptor activation has been 
demonstrated to have multiple eff ects in 
a variety of tissues. 1 Th ese pleiotropic 
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effects may limit bone loss, but also 
reduce mortality in patients with kidney 
disease, and possibly attenuate the rate 
of progression of renal disease. The 
explanation for these benefi ts is elusive 
but may involve not only diminished lev-
els of parathyroid hormone but perhaps 
attenuation of hormonal and proinfl am-
matory systems that may promote scar-
ring and fi brosis ( Figure 1 ). Despite the 
observed benefi ts with regard to mortal-
ity in patients with kidney disease, 2 and 
the reduction of albuminuria, 3 which is 
a perceived surrogate of renal protection, 
a lingering concern is the evidence in a 
number of patients of a decline in esti-
mated glomerular fi ltration rate. Might 
the pleiotropic effects of vitamin D 
receptor activation possess both benefi -
cial and detrimental eff ects on kidney 
function? 
 Experimental studies have demon-
strated that inadequate vitamin D 
receptor activation worsens diabetic 
nephropathy through increased fi bronec-
tin production and decreased nephrin 
expression. 4 Moreover, vitamin D recep-
tor activation suppresses high-glucose-
induced activation of the renin – angiotensin 
system and transforming growth factor-
  . 5 In other experimental models of 
nephropathy, vitamin D receptor activa-
tion attenuates renal interstitial fi brosis 
and limits epithelial-to-mesenchymal 
transition. 6 
 In clinical studies, vitamin D receptor 
activation facilitates an antiproteinuric 
response that is incremental to blood 
pressure reduction and renin – angi-
otensin system blockade. 3 Yet the increase 
in serum creatinine observed during 
these studies raises important questions 
about the overall long-term benefi t of 
vitamin D receptor activation for kidney 
function. 
 A number of important clues in the 
clinical literature provide perspective. 
First, the eff ect of vitamin D on serum 
creatinine was reversible aft er the cessa-
tion of therapy. 7 Second, in small studies, 
the reduction in creatinine clearance 
associated with vitamin D therapy was 
not seen in patients who had simultane-
ous measurement of glomerular fi ltration 
rate. 7 Th ird, other older studies, albeit 
small, have suggested that vitamin D 
receptor activation may alter creatinine 
metabolism and / or its handling by the 
kidney. 8 Consequently, the small but 
well-done study by Agarwal  et al. 9 (this 
issue), in which they examined the eff ect 
of vitamin D receptor activation on cre-
atinine metabolism and measured 
glomerular fi ltration rate, and its revers-
ibility, is quite important. 
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 Although only 16 patients with 
chronic kidney disease were studied, 
Agarwal and colleagues 9 were able to 
demonstrate that a 7-day course of 
paricalcitol (2   g daily) resulted in an 
increase in serum creatinine and urine 
creatinine, while creatinine clearance 
did not change. Simultaneous measure-
ment of glomerular filtration rate with 
iothalamate was not altered by parical-
citol therapy. Moreover, within 4 days 
of cessation of vitamin D therapy, the 
observed changes in creatinine genera-
tion and serum creatinine reversed 
back to near the baseline. In parallel 
with these changes were effects on both 
urea nitrogen excretion rate and serum 
urea nitrogen, indicating an early ana-
bolic response to vitamin D receptor 
activation. Thus, there may be parallel 
effects of vitamin D receptor activation 
on protein and creatinine metabolism. 
These observations are not entirely sur-
prising given older reports indicating 
that muscle tissue is a target of vitamin 
D receptor stimulation. 10 Small clinical 
studies have demonstrated that vitamin 
D treatment improves myopathy in 
patients with bone loss and results 
in increased muscle strength and gait 
and reduces falls. 11 It is conceivable 
that some of the beneficial impact of 
vitamin D receptor activation on sur-
vival in patients with chronic kidney 
disease could be related to its anabolic 
effects to improve skeletal and myo-
cardial muscle function. This may be 
particularly important in patients with 
early evidence of either skeletal or myo-
cardial muscle dysfunction. One has to 
wonder whether vitamin D receptor 
stimulation could even prevent muscle 
atrophy in patients with chronic kidney 
disease. 
 The importance of this small and 
straightforward study by Agarwal  et al. 9 
is that vitamin D receptor activation must 
be considered, at least in the short term, 
as a factor that can infl uence creatinine 
meta bolism. Th us, changes of serum cre-
atinine, or a serum creatinine-based esti-
mation of glomerular filtration rate, 
needs to be cautiously considered in 
patients receiving activated vitamin D. As 
we have learned with renin – angiotensin 
system blockers, which can induce a 
functional change in glomerular fi ltration 
rate that can be misinterpreted as nephro-
toxicity, so can vitamin D receptor activa-
tion alter creatinine metabolism in a 
manner that could be misperceived as 
potential nephrotoxicity. However, as the 
authors appropriately point out, one 
should interpret these observations with 
care given that this is a small, short-term 
study. Th e observations that they provide 
in this important paper should prompt 
planning for longer-term trials of the 
overall infl uence of vitamin D receptor 
activation on protein and creatinine 
meta b olism in patients with chronic kid-
ney disease. Th ese anabolic eff ects may 
help explain why vitamin D receptor acti-
vation may have beneficial effects on 
mortality in patients with chronic kidney 
disease. 
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 Figure 1  |  The relationship between vitamin D receptor activation, inflammation, renal and 
cardiac benefits, and protein and creatinine metabolism in patients with chronic kidney 
disease. 
